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Abstract
Chronic kidney disease (CKD) is an important cause of morbidity and mortality in HIV-positive individuals. Hepatitis C (HCV)
co-infection has been associated with increased risk of CKD, but prior studies lack information on potential mechanisms. We
evaluated the association between HCV or hepatitis B (HBV) co-infection and progressive CKD among 3,441 antiretroviral-
treated clinical trial participants. Progressive CKD was defined as the composite of end-stage renal disease, renal death, or
significant glomerular filtration rate (eGFR) decline (25% decline to eGFR ,60 mL/min/1.73 m2 or 25% decline with a
baseline ,60). Generalized Estimating Equations were used to model the odds of progressive CKD. At baseline, 13.8% and
3.3% of participants were co-infected with HCV and HBV, respectively. Median eGFR was 111, and 3.7% developed
progressive CKD. After adjustment, the odds of progressive CKD were increased in participants with HCV (OR 1.72, 95% CI
1.07–2.76) or HBV (OR 2.26, 95% CI 1.15–4.44). Participants with undetectable or low HCV-RNA had similar odds of
progressive CKD as HCV seronegative participants, while participants with HCV-RNA .800,000 IU/ml had increased odds
(OR 3.07; 95% CI 1.60–5.90). Interleukin-6, hyaluronic acid, and the FIB-4 hepatic fibrosis index were higher among
participants who developed progressive CKD, but were no longer associated with progressive CKD after adjustment. Future
studies should validate the relationship between HCV viremia and CKD.
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Introduction
In 2006, ten years after the widespread introduction of effective
combination antiretroviral therapy (cART) for the treatment of
human immunodeficiency virus (HIV) infection, the randomized
Strategies for Management of Antiretroviral Therapy trial
(SMART) established uninterrupted cART with the goal of
continuous viral suppression as the standard of care. [1] Although
the primary outcome of SMART focused on mortality and
opportunistic illness associated with acquired immunodeficiency
syndrome (AIDS), the results also highlighted the growing burden
of comorbid disease in the cART era. During an average follow-up
of 16 months, serious cardiac, liver, and kidney events were more
common than serious AIDS-defining events, regardless of treat-
ment assignment. [1].
Chronic kidney disease (CKD) has been associated with
increased morbidity and mortality in HIV-positive individuals
receiving cART. [2–3] In addition to traditional CKD risk factors
such as diabetes and hypertension, co-infection with hepatitis C
virus (HCV) has been suggested as a possible risk factor for CKD
in HIV-positive individuals. [4] Although there are conflicting
data on the relationship between HCV infection and CKD in the
general population, meta-analysis of published studies in HIV-
positive populations supports an association between HIV-HCV
co-infection and increased risk of CKD. [5] The relationship
between hepatitis B virus (HBV) infection and CKD has not been
as extensively studied, although cross-sectional studies have not
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demonstrated an association between HBV mono-infection and
prevalent CKD. [6–7].
Both HBV and HCV have been implicated in the pathogenesis
of specific immune complex kidney diseases in the general
population and in HIV-positive individuals,[8–11] and clinically
silent immune complex kidney disease has been observed in HCV
mono-infected patients with end-stage liver disease. [12] End-stage
liver disease has also been associated with increased risk of overt
CKD in HCV-infected individuals, although data on the relative
contribution of immune complex disease and hepatorenal
syndrome were not available. [13] Previous studies have not
investigated other potential mediators of the relationship between
viral hepatitis and CKD, including earlier stages of hepatic fibrosis
and liver dysfunction, increased levels of systemic inflammation, or
nephrotoxic effects of antiviral therapy for HBV or HCV. In
addition, the majority of prior studies defined viral hepatitis co-
infection by serology alone, and did not report data on HBV
DNA, HCV RNA, or HCV genotype as potential mediators or
effectors of the relationship between viral hepatitis and CKD.
We evaluated the association between viral hepatitis co-infection
and progressive CKD among 3,441 cART-treated participants
enrolled in two large international HIV treatment trials, with the
goal of identifying potential mediators of the relationship.
Methods
Study Population
The study designs of SMART and the Evaluation of Subcuta-
neous Proleukin in a Randomized International Trial (ESPRIT)
have been described previously. [1,14] Briefly, SMART random-
ized 5,472 HIV-positive adults with CD4 cell count (CD4) .350
cells/mm3 to receive uninterrupted cART with the goal of viral
suppression versus episodic cART guided by CD4. SMART was
stopped early because of a safety risk in the episodic therapy arm.
[1] ESPRIT randomized 4,111 HIV-positive adults with
CD4.300 cells/mm3 to receive cART alone or in combination
with subcutaneous interleukin-2. ESPRIT failed to demonstrate a
clinical benefit of interleukin-2 despite an increase in CD4. [14]
For consistency with standards of care, the current analysis
included only participants randomized to the viral suppression
arm of SMART and the control arm of ESPRIT. Baseline was
defined as the date of randomization into SMART or ESPRIT.
Eligible participants with plasma specimens available for central-
ized measurement of creatinine at baseline and at least one
subsequent study visit were included in this analysis.
Definition of Study Endpoints and Covariates
Plasma specimens were collected in EDTA tubes, aliquoted, and
shipped frozen to a central repository. Available specimens from
the randomization (‘‘baseline’’), 12-month, and subsequent annual
visits were retrieved for centralized creatinine testing using an
isotope dilution mass spectrometry (IDMS)-traceable enzymatic
assay (Roche Creatinine Plus in SMART and Diazyme Liquid
Reagents Creatinine Assay in ESPRIT). The eGFR was calculated
from centralized creatinine values using the Chronic Kidney
Disease Epidemiology Consortium (CKD-EPI) equation. [15] In a
sensitivity analysis, we explored the impact of adjusting eGFR in
Asian participants using a correction coefficient of 0.813, as
suggested for Japanese individuals, [16] or of 1.052, which was
shown to improve the bias of the CKD-EPI equation among
Chinese individuals. [17].
For the purposes of this analysis, progressive CKD was defined
as the composite of end-stage renal disease (ESRD), renal death, or
significant decline in eGFR (25% decline in eGFR to a level
#60 mL/min/1.73 m2 in participants with a baseline eGFR
.60 mL/min/1.73 m2 or a 25% decline in eGFR for those with a
baseline eGFR ,60 mL/min/1.73 m2). To address the potential
misclassification of acute kidney injury in participants with a 25%
decline in eGFR based on a single follow-up creatinine value, we
performed a sensitivity analysis requiring a confirmed 25% decline
in eGFR based on at least 2 consecutive values.
Hepatitis co-infection was defined serologically at baseline,
based on the detection of HBV surface antigen (HBsAg) or anti-
HCV antibody. Additional testing was performed in participants
with serologic evidence of HBV or HCV co-infection, including
HBV-DNA or HCV-RNA and HCV genotype, respectively.
Relevant comorbid conditions were defined at baseline. Hyper-
tension, diabetes, and hyperlipidemia were defined by the self-
reported use of medications to treat these conditions. Cardio-
vascular disease was defined by self-reported medical treatment
or a history of coronary revascularization, myocardial infarction,
or cerebrovascular accident prior to baseline. Plasma hyaluronic
acid was measured as a circulating marker of hepatic fibrosis in
co-infected participants, [18] and the FIB-4 and APRI fibrosis
indices were calculated for all participants with available data at
baseline.[19–20] The systemic inflammatory markers IL-6 and
hsCRP were also measured at baseline in approximately 70% of
participants, independent of hepatitis status.
Statistical Methods
Descriptive statistics were used to compare baseline character-
istics between participants enrolled in SMART and ESPRIT, and
between participants who did or did not develop progressive
CKD. A descriptive analysis was also performed to compare the
proportion of participants with progressive CKD at yearly
intervals. The odds of progressive CKD were investigated using
Generalised Estimating Equations, using binomial regression and
adjusting for repeated measurements per person. Participants were
included in analyses until the development of progressive CKD or
the last eGFR measurement. In addition to HBV or HCV co-
infection, other potential explanatory variables included age, sex,
race, HIV exposure category, history of AIDS-defining illness,
presence of other relevant comorbid conditions, HIV-RNA, CD4,
CD4 nadir, body mass index (BMI), eGFR, and the use of cART
both prior to and at randomization into the parent trial. Any
explanatory variables with p,0.1 in univariate analyses were
included in multivariate analyses. Excluded variables were tested
in the final model to determine if their inclusion improved the
model fit. Separate sensitivity analyses were performed including
time-updated (‘‘on-treatment’’) variables for selected antiretroviral
agents, and including only participants with progressive CKD as
defined by a clinical CKD event or a confirmed decline in eGFR
based on two consecutive measures.
Further analyses focused on the role of baseline HBV or HCV
viremia and HCV genotype as explanatory variables; HBV and
HCV viremia were also explored as time-updated variables.
Exploratory analyses using the same methods investigated the role
of baseline hyaluronic acid, APRI, FIB-4, IL6 and hsCRP.
Separate multivariate models were run for each of these markers
to minimize the impact of missing data; as a result, the presented
results were not mutually adjusted for the other markers.
Multivariate models were adjusted for the same factors that were
found to be of importance in the main analysis.
Results
A total of 4,792 participants were enrolled in the standard
therapy arms of SMART and ESPRIT. [1,14] After excluding 971
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participants with no centralized plasma creatinine at enrollment
(‘‘baseline’’) and an additional 380 participants with no subsequent
centralized creatinine, 3,441 participants (72%) were included in
the current analysis (2,054 from SMART and 1,387 from
ESPRIT). Compared to those excluded, included participants
were less likely to report their race as white and more likely to be
enrolled in ESPRIT, had lower CD4+ T-cell count (CD4) nadirs,
were randomized later, and were more likely to be on lipid-
lowering therapy. The prevalence of serologically defined HBV
and HCV co-infection was similar in excluded and included
participants.
A total of 11,050 follow-up plasma creatinine values were
available to calculate estimated glomerular filtration rate (eGFR),
a median of 3 (interquartile range [IQR] 2–5) per participant.
There were more creatinine measurements available in partici-
pants from ESPRIT compared to SMART (median 5 versus 2
respectively, p,0.0001), consistent with the longer follow-up
period, and in those who developed progressive CKD compared
to those who did not (median 5 versus 3 respectively, p,0.001).
The median time between measurements was 1 year (IQR 1.0–
1.1), with no difference between trials (p = 0.59) and in those who
did and did not develop CKD (p= 0.22). Other characteristics
associated with more available creatinine measurements included
lower baseline CD4, higher nadir CD4, prior AIDS diagnosis,
older age, and non-white race.
Baseline Characteristics of the Study Population
Table 1 summarizes the characteristics of the study population
at randomization into SMART or ESPRIT, comparing those who
did and did not develop progressive CKD. There were a total of
114 participants (3.3%) with serologic evidence of HBV co-
infection as defined by HBV surface antigen (HBsAg) and 473
(13.8%) participants with serologic evidence of HCV co-infection
as defined by anti-HCV antibody. The prevalence of HBV co-
infection was higher in ESPRIT participants (5.3% versus 2.0%),
while the prevalence of HCV co-infection was similar across trials.
At baseline, 2,999 (87.2%) participants had an eGFR .90 mL/
min/1.73 m2, and 57 participants (1.7%) had an eGFR ,60 mL/
min/1.73 m2. The proportions with normal and decreased eGFR
were similar across trials. Participants in SMART were more likely
to report their race as black, more likely to report comorbid
diabetes, hypertension, and cardiovascular disease, and less likely
to have suppressed HIV-RNA.
Development of Progressive CKD
A total of 127 participants (3.7%) developed progressive CKD.
The majority of events occurred in participants with a baseline
eGFR .60 mL/min/1.73 m2 (n= 119). Nearly all events were
defined by eGFR decline (n = 125), although three of these
participants subsequently developed ESRD during follow-up. Two
additional participants developed a clinical event without a
documented decline in eGFR of at least 25% (one case of ESRD
and one renal death). Forty-two events (2.0%) occurred in
SMART participants and 85 events (6.1%) occurred in ESPRIT
participants (p,0.0001). For descriptive purposes, Figure 1 shows
the cumulative proportion of participants with progressive CKD
each year after baseline, overall and stratified according to the
presence of HBV or HCV co-infection. The proportion with
progressive CKD was higher among participants with HBV or
HCV co-infection at all time points. In univariate analysis, both
HBV and HCV co-infection were associated with increased odds
of progressive CKD (Table 2). No CKD events occurred in the
small number of participants co-infected with both HBV and
HCV (n= 16).
In multivariate analysis adjusting for baseline characteristics, the
odds of developing progressive CKD were significantly increased
in participants with HBV (adjusted OR 2.26, 95% CI 1.15–4.44)
or HCV co-infection (adjusted OR 1.72, 95% CI 1.07–2.76).
Other factors associated with increased odds of progressive CKD
included black or Asian race, older age, and self-reported use of
antihypertensive medications. Higher baseline eGFR and higher
CD4 nadir were associated with lower odds of developing
progressive CKD, as was a later date of randomization into the
parent trial.
Sensitivity Analyses
In sensitivity analysis, the inclusion of time-updated ‘‘on-
treatment’’ variables for potentially nephrotoxic antiretroviral
agents (atazanavir, indinavir, boosted lopinavir, and tenofovir) and
agents with dual activity against HIV and HBV (lamivudine and
emtricitabine) did not significantly affect the relationship between
progressive CKD and HBV (adjusted OR 2.20, 95% CI 1.13–
2.89) or HCV co-infection (adjusted OR 1.77, 95% CI 1.08–2.89).
In a separate sensitivity analysis including 2,659 participants with
at least 2 centralized creatinine values during follow-up, 30
participants (1.1%) developed progressive CKD as defined by a
clinical event or a decline in eGFR confirmed on two consecutive
measures. In adjusted analysis, the odds ratios associated with
hepatitis virus co-infection were similar to the primary analysis but
no longer reached statistical significance (HBV co-infection 1.94,
95% CI 0.46–8.18; HCV co-infection 1.73, 95% CI 0.61–4.89).
Other relationships were consistent with the results of the primary
analysis (data not shown). In a final sensitivity analysis, we
explored the impact of adjusting eGFR in Asian participants using
recommended correction coefficients for Japanese and Chinese
populations.[16–17] While these adjustments impacted the num-
ber of CKD events in Asian participants, the relationships between
HBV, HCV, Asian race, and progressive CKD were similar to the
primary analysis.
Planned Subgroup Analysis of Participants with HBV or
HCV Co-infection
Participants with serologic evidence of HBV co-infection were
further stratified by the presence or absence of detectable HBV
DNA at baseline, with a cutoff of ,357 IU/ml (Figure 2). Among
70 participants with detectable HBV DNA, the median HBV
DNA was 7.3 (IQR 5.3–7.3) log10 copies/mL. After adjustment for
the variables in Table 2, participants with serologic evidence of
HBV co-infection had similar odds of developing progressive
CKD regardless of whether HBV DNA was undetectable (adjusted
OR 2.16; 95% CI 0.84–5.55) or detectable at baseline (adjusted
OR 2.33; 95% CI 0.97–5.58), but this failed to reach statistical
significance in these smaller subgroups. Because of the small
number of participants with HBV co-infection, it was not possible
to further stratify viremic participants or to explore the role of
HBV rebound during follow-up.
Participants with serologic evidence of HCV co-infection were
further stratified into those with undetectable HCV RNA, low
HCV RNA (#800,000 IU/ml), and high HCV RNA
(.800,000 IU/ml). After adjustment, participants with undetect-
able HCV RNA (adjusted OR 0.91, 95% CI 0.30–2.79) or with
low HCV RNA (adjusted OR 1.41; 95% CI 0.71–2.79) had
similar odds of developing progressive CKD as those with a
negative HCV antibody result, while participants with high HCV
RNA had significantly increased odds (adjusted OR 3.07; 95% CI
1.60–5.90). Among those with HCV co-infection, the test for trend
moving from those with undetectable HCV RNA to those with
high HCV RNA was marginally statistically significant (p = 0.057).
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Similar results were seen when RNA levels were stratified by the
median value (585,000 IU/ml) among viremic participants (data
not shown). Further stratification of HCV RNA levels by quartiles
suggested a gradual increase in risk of progressive CKD associated
with increasing HCV RNA levels. The test for trend was again
marginally statistically significant (p = 0.066), and the small
number of events in each stratum meant that the confidence
intervals for individual strata were wide (Figure 3). Among 353
participants with known HCV genotype, there were no differences
in the odds of developing progressive CKD in those with genotype
1 versus other genotypes (Figure 2).
Circulating levels of hyaluronic acid, as well as the calculated
FIB-4 index of hepatic fibrosis, were significantly higher at
baseline among participants who subsequently developed progres-
sive CKD, while there was no significant difference in the
aspartate aminotransferase platelet ratio index (APRI). None of
the markers of hepatic fibrosis remained significantly associated
with progressive CKD after adjustment for other important
Table 1. Baseline characteristics of study participants, stratified by the development of progressive chronic kidney disease (CKD).
All
(n = 3,441)
No progressive CKD
(n=3,314)
Progressive CKD
(n=127) p
Median age Years 43 36,47 42 36,39 48 39,55 ,0.0001
Male sex 2638 76.7 2544 76.8 94 74.0 0.47
Race Black 693 20.1 663 20.0 30 23.6 ,0.0001
Asian 206 6.0 185 5.6 21 16.5 –
White 2280 66.3 2211 66.7 69 54.4 –
Other 262 7.6 255 7.7 7 5.5 –
Exposure category Intravenous drug use 331 9.6 315 9.5 17 13.4 0.14
Heterosexual contact 1387 40.3 1331 40.2 56 44.1 0.38
Same sex contact 1812 52.7 1745 53.0 56 44.1 0.049
Median CD4 cells/mm3 524 414, 700 526 415, 702 457 390, 570 ,0.0001
Median nadir CD4 cells/mm3 223 114, 330 226 117, 333 153 87, 262 ,0.0001
HIV RNA ,500 copies/mL1 2626 76.5 2533 76.6 93 73.2 0.38
History of AIDS 906 26.3 862 26.0 44 34.7 0.030
Antiretroviral naı¨ve 786 22.8 765 23.1 21 16.5 0.085
Specific antiretrovirals
Atazanavir use At randomization 128 3.7 128 3.9 0 0 0.024
Prior history 29 0.8 28 0.8 1 0.8 0.94
Indinavir use At randomization 304 8.8 283 8.5 21 16.5 0.0018
Prior history 980 28.5 942 28.4 38 29.9 0.71
Ritonavir use At randomization 413 12.0 395 11.9 18 14.2 0.44
Prior history 603 17.5 578 17.4 25 19.7 0.51
Tenofovir use At randomization 419 12.2 411 12.4 8 6.3 0.039
Prior history 84 2.4 82 2.5 2 1.6 0.52
Hepatitis C virus Antibody positive+2 473 13.8 448 13.5 25 19.7 0.049
RNA positive3 363 77.1 342 76.7 21 84.0 0.40
RNA .800,000 151 32.1 139 31.1 12 48.0 0.079
Genotype 13 258 73.1 240 72.3 18 85.7 0.18
Hepatitis B virus Surface antigen positive1 114 3.3 100 3.0 14 11.0 ,0.0001
DNA positive 70 61.4 62 62.0 8 57.1 0.73
Median eGFR ml/min/1.73 m2 111 100, 121 112 101, 121 91 79, 106 ,0.0001
Median BMI kg/m2 24 22, 27 24 22, 27 24 22, 27 0.19
Comorbid conditions Diabetes mellitus 177 5.1 159 4.8 18 14.2 ,0.0001
Antihypertensive therapy 447 13.0 415 12.5 32 25.2 ,0.0001
Lipid-lowering therapy 501 14.6 475 14.3 26 20.5 0.054
Cardiovascular disease 114 3.3 109 3.3 5 3.9 0.69
Baseline was defined at randomization into the parent trial (SMART or ESPRIT).
Categorical variables are presented as N (%) and continuous variables presented as median (interquartile range).
1Data on HIV RNA and Hepatitis B surface antigen were available for 3435 participants (99.8%).
2Data on Hepatitis C antibody status were available for 3436 participants (99.8%).
3Among 473 participants with positive Hepatitis C antibody, RNA viral load was available for 471 (99.6%) and genotype was available for 353 (74.6%).
eGFR, estimated GFR calculated using the CKD-EPI formula; BMI, body mass index.
doi:10.1371/journal.pone.0040245.t001
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variables (Table 3). The small number of participants with
significant elevations in these markers precluded consideration of
clinically relevant cutoff values. As previously reported, the
systemic inflammatory markers high sensitivity C-reactive protein
(hsCRP) and interleukin-6 (IL-6) were not significantly associated
with progressive CKD in this population after adjustment for other
Figure 1. Cumulative proportion of participants with progressive kidney disease.
doi:10.1371/journal.pone.0040245.g001
Table 2. Baseline characteristics associated with progressive CKD in univariate and multivariate analysis.
Univariate Multivariate
Odds Ratio 95% CI Odds Ratio 95% CI
Hepatitis B surface antigen positive 3.28 1.90–5.67 2.26 1.15–4.44
Hepatitis C antibody positive 1.58 1.02–2.44 1.72 1.07–2.76
Age, per 10 years 1.69 1.41–2.02 1.36 1.10–1.68
Race
Black 1.59 1.04–2.45 2.07 1.23–3.49
Asian 2.43 1.49–3.97 2.33 1.19–4.55
Other 0.97 0.45–2.11 1.27 0.57–2.83
Same sex exposure 0.70 0.49–0.99 0.76 0.51–1.13
CD4, per 100 cells/mm3 0.88 0.80–0.97 1.00 0.90–1.11
Nadir CD4, per 100 cells/mm3 0.79 0.70–0.89 0.84 0.72–0.98
History of AIDS 1.51 1.05–2.17 1.13 0.74–1.72
Antiretroviral naı¨ve 0.65 0.41–1.04 0.80 0.49–1.30
Current or previous indinavir use 1.68 1.05–2.70 0.76 0.43–1.34
Antihypertensive therapy 2.62 1.75–3.90 1.83 1.14–2.94
Lipid-lowering therapy 1.61 1.04–2.47 1.28 0.80–2.05
eGFR, per 5 ml/min/1.73 m2 0.82 0.80–0.85 0.85 0.82–0.87
Enrolled in ESPRIT 1.77 1.22–2.56 1.77 0.90–3.49
Date of randomization, per year 0.80 0.71–0.90 0.81 0.67–0.98
doi:10.1371/journal.pone.0040245.t002
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variables (Abstract # O-271, Conference on Retroviruses and
Opportunistic Infections 2012). The relationships between HBV
and HCV co-infection and progressive CKD were not significantly
affected by inclusion of any individual marker of hepatic fibrosis or
systemic inflammation in separate multivariate models (data not
shown).
Post-hoc Subgroup Analyses
Because of the unexpected relationship between HBV co-
infection and progressive CKD, this relationship was further
investigated after stratification by race and by clinical trial. After
adjustment, HBV co-infection was associated with a greater than
6-fold increased odds of CKD in SMART and a 1.5-fold increased
odds in ESPRIT, but there was no evidence that the adjusted OR
was significantly different between the trials (p = 0.12 for
interaction). When stratified by race, the odds of progressive
CKD associated with HBV co-infection were highest in black
participants (OR 14.54, 95% CI 4.16–50.85) and lowest in Asian
participants (adjusted OR 1.26, 95% CI 0.36–4.47), although this
difference was not statistically significant (p = 0.67 for interaction).
We also considered the use of antiviral agents with dual activity
against HIV and HBV, as well as the use of antiviral agents for the
treatment of HBV. Among 114 participants with HBV co-
infection, 12 (10.5%) were taking tenofovir, 76 (66.7%) were
taking lamivudine, and none were taking emtricitabine at baseline.
One additional participant reported prior use of tenofovir, and 31
reported prior use of lamivudine. There were no differences
between participants with and without HBV co-infection in the
use of these agents at or prior to baseline (p.0.05 all comparisons).
As described above, the inclusion of ‘‘on-treatment’’ variables for
these agents did not affect the relationship between HBV and
progressive CKD in sensitivity analysis. Among 74 ESPRIT
participants with HBV, none reported the use of adefovir at
baseline; data on the use of adefovir were not routinely collected in
SMART. The anti-HBV agents entecavir and telbivudine were
not approved for clinical use during enrollment in the parent trials.
Discussion
In this analysis of data and specimens from two large
randomized HIV treatment trials, co-infection with either HCV
or HBV was independently associated with progressive CKD
among HIV-positive adults receiving cART. After adjusting for
other important characteristics, the relationship between viral
hepatitis co-infection and CKD did not appear to be mediated by
mild hepatic fibrosis or by systemic inflammation. Increasing
plasma HCV RNA, but not HBV DNA, was an independent
predictor of progressive CKD. These results support current
guidelines that consider HCV co-infection a risk factor for CKD.
[4] The observed relationship between HCV viremia and CKD is
also consistent with a recent report from a large European HIV
cohort. [21] If confirmed in future studies, the relationship
between HCV RNA and CKD may provide an additional impetus
Figure 2. Association of Hepatitis B and C viremia and Hepatitis C genotype with progressive kidney disease. Final models were
adjusted for trial, age, race, infection through same sex exposure, prior AIDS diagnosis, CD4, CD4 nadir, previous exposure to antiretrovirals, previous
exposure to indinavir, treatment with antihypertensives, treatment with lipid lowering therapy, estimated glomerular filtration rate, and year of
randomization, all measured at randomization into the parent trial. As appropriate, analyses were also adjusted for 1Hepatitis C (HCV) antibody status
or 2 Hepatitis B surface antigen (HBsAg) status. Participants with positive HBsAg were further stratified by the presence or absence of detectable HBV
DNA, with a cutoff of ,357 IU/ml. The number of patients (events) for HBsAg negative, positive with HBV DNA ,357 IU/mL, and positive with HBV
DNA $357 IU/ml were 3321 (113), 44 (6), and 70 (8), respectively. Participants with positive HCV antibody were further stratified into those with
undetectable HCV RNA, low HCV RNA (#800,000 IU/ml), and high HCV RNA (.800,000 IU/ml). The number of patients (events) for HCV antibody
negative, positive with undetectable HCV RNA, low HCV RNA, and high HCV RNA were 2963 (102), 108 (4), 212 (9), and 151 (12), respectively. The
analysis of HCV genotype was limited to participants with positive HCV antibody and known HCV genotype, stratified as genotype 1 (258 patients, 18
events) or other (95 patients, 3 events).
doi:10.1371/journal.pone.0040245.g002
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for antiviral therapy as newer agents become available for the
treatment of HCV co-infection.
Although we observed an unexpected relationship between
serologic evidence of HBV co-infection and progressive CKD, this
relationship did not appear to require active HBV replication at
baseline. More refined stratification of baseline HBV DNA and
consideration of viral rebound during follow-up were limited by
the small number of patients with active HBV. In addition, HBV e
antigen (HBeAg) and quantitative HBsAg were not measured, and
HBV DNA was only measured in participants with serologic
evidence of HBV infection. Data on the use of adefovir for the
treatment of HBV were not collected in SMART, so it was not
possible to exclude an effect of this potentially nephrotoxic
antiviral agent. Adjustment for the use of tenofovir, which may
have been used preferentially in the setting of HBV co-infection,
did not change our findings.
Suppression of HBV replication with interferon or lamivudine
has been associated with remission of kidney disease in some, but
not all, cases of HBV-related immune complex kidney disease.[22–
23] The pathogenesis of HBV-related kidney disease is hypoth-
esized to involve the deposition of HBeAg in glomerular
capillaries. [8] Although we were unable to explore this hypothesis
in the current study, it is possible that circulating HBV antigens
may continue to deposit in the kidney, or that previously deposited
antigens may continue to trigger an immune response in the
kidney, even in the absence of active HBV replication. This effect
Figure 3. Association of Hepatitis C viremia with progressive kidney disease. Hepatitis C (HCV)-RNA was further stratified by quartiles to
determine whether there is clinically useful threshold HCV-RNA level associated with increased risk of progressive kidney disease. The number of
patients (events) included for HCV antibody negative and for increasing quartiles of HCV-RNA were 2963 (102), 108 (4), 154 (7), 102 (7), and 107 (7),
respectively. Final models were adjusted for trial, age, race, infection through same sex exposure, prior AIDS diagnosis, CD4, CD4 nadir, previous
exposure to antiretrovirals, previous exposure to indinavir, treatment with antihypertensives, treatment with lipid lowering therapy, estimated
glomerular filtration rate, year of randomization, and Hepatitis B surface antigen status, all measured at randomization into the parent trial.
doi:10.1371/journal.pone.0040245.g003
Table 3. Markers of hepatic fibrosis as proposed mediators of progressive chronic kidney disease (CKD).
No progressive CKD Progressive CKD Univariate Multivariate
Median (IQR) Median (IQR) OR 95% CI OR 95% CI
Hyaluronic acid1 25 (15, 44) 36 (17, 72) Per 20 higher 1.05 1.02, 1.08 1.00 0.98, 1.03
APRI2 0.27 (0.19, 0.40) 0.30 (0.21, 0.49) Per 1 higher 1.02 0.95, 1.11 1.04 0.89, 1.21
FIB43 0.86 (0.63, 1.19) 1.08 (0.74, 1.51) Per 1 higher 1.02 0.99, 1.06 0.97 0.71, 1.33
Data available for 1n = 827,
2n = 1421,
3n = 1268.
The number of participants who developed progressive kidney disease was 1n = 42,
2n = 73,
3n = 63.
APRI, aspartate aminotransferase platelet ratio index.
doi:10.1371/journal.pone.0040245.t003
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may be magnified in patients with HIV co-infection, who are less
likely to clear HBV antigens even when HBV DNA is suppressed.
[24] Future studies should collect data on proteinuria, hematuria,
and circulating markers of immune complex disease [8–11] in
order to evaluate this hypothesis.
In addition to the novel relationships observed in this study,
progressive CKD was also associated with traditional CKD risk
factors. Other characteristics that were independently associated
with progressive CKD included older age, black race, and
hypertension, as well as lower baseline eGFR and lower nadir
CD4. These findings are consistent with expert guidelines that
recommend increased frequency of CKD screening in individuals
with these risk factors. [4] Diabetes was rare in our population,
and did not remain independently associated with progressive
CKD in multivariate analysis. Female sex and body mass index
(BMI) at baseline were not associated with progressive CKD in our
population, in contrast to some prior studies in HIV-positive
populations.[25–26] Of note, very low BMI was rare and women
made up less than a quarter of our study population. While Asian
race has not been associated with CKD in the setting of HIV
infection, Asian nations report some of the highest incidence rates
of ESRD in the general population. [27].
Strengths of the current analysis include a large patient
population treated according to the standard of care for HIV
infection, centralized measurement of serum creatinine, adjust-
ment for markers of HIV disease severity, and inclusion of data on
HBV and HCV viremia. Despite these strengths, several
limitations should be considered when interpreting the results of
this study. Most importantly, this was a secondary analysis of data
from randomized clinical trials designed to evaluate non-renal
outcomes. Nonetheless, all clinical events were reviewed centrally,
and the majority of clinically relevant CKD events were captured
based on eGFR decline. It is more likely that we misclassified acute
events using the eGFR criteria; however, we obtained similar
results in a sensitivity analysis that required confirmation of eGFR
decline on two consecutive measures. Second, we had incomplete
data on markers of hepatic fibrosis and systemic inflammation.
Although we did not observe a relationship between these markers
and progressive CKD, clinically significant hepatic fibrosis was
rare in this population of clinical trial participants. Because of the
small number of participants with elevated markers of hepatic
fibrosis, we were also unable to dichotomize these markers at
clinically relevant cutoffs. [13] Third, we were unable to fully
adjust for cumulative exposure to tenofovir and other potentially
nephrotoxic antiretroviral agents, [28] although the inclusion of
time-updated ‘‘on treatment’’ variables for these agents did not
affect the relationship between HBV or HCV co-infection and
progressive CKD. This may have lead to some residual
confounding, particularly in the observed association between
HBV co-infection and progressive CKD. Of note, tenofovir and
atazanavir were infrequently used at the time of enrollment in the
parent studies, and this study was not powered to exclude an
association of these agents with CKD. Fourth, we were unable to
account for the duration and type of injection drug use as potential
confounders of the relationship between HBV or HCV co-
infection and progressive CKD. Injection drug use was reported as
a risk factor for HIV exposure in fewer than 10% of participants,
and exposure history was included in our adjusted analyses.
Finally, we were unable to adjust for proteinuria and blood
pressure, as these data were not collected in SMART and
ESPRIT. Proteinuria is a strong predictor of CKD progression in
HIV-positive individuals, [29] and HCV mono-infection has been
associated with increased prevalence of proteinuria. [30] Hyper-
tension, as defined by the use of antihypertensive medication at
baseline, was associated with progressive CKD in our population.
Unfortunately, data on the use of specific antihypertensive agents
were not rigorously collected in these HIV treatment trials, and we
were unable to consider potential risks or benefits associated with
specific agents or classes. [4].
In summary, in this large cohort of HIV-positive clinical trial
participants, co-infection with either HBV or HCV was indepen-
dently associated with progressive CKD. The observed relation-
ship did not appear to be mediated by early hepatic fibrosis or by
increased systemic inflammation in co-infected individuals,
although we were unable to exclude a role for more advanced
liver disease in this relatively healthy population. Active HCV
replication was an independent predictor of progressive CKD, and
future trials of direct acting antivirals for HCV should consider the
impact of successful antiviral treatment on the risk of CKD in co-
infected individuals. Future studies are needed to confirm the
observed relationship between HBV co-infection and progressive
CKD.
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